JP2018203747A5 - - Google Patents

Download PDF

Info

Publication number
JP2018203747A5
JP2018203747A5 JP2018150978A JP2018150978A JP2018203747A5 JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5 JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
cholesterol
diabetes
use according
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018150978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018203747A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018203747A publication Critical patent/JP2018203747A/ja
Publication of JP2018203747A5 publication Critical patent/JP2018203747A5/ja
Priority to JP2021103893A priority Critical patent/JP2021155436A/ja
Priority to JP2023146755A priority patent/JP2023178518A/ja
Pending legal-status Critical Current

Links

JP2018150978A 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法 Pending JP2018203747A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021103893A JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015505963A Division JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103893A Division JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法

Publications (2)

Publication Number Publication Date
JP2018203747A JP2018203747A (ja) 2018-12-27
JP2018203747A5 true JP2018203747A5 (https=) 2019-05-16

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (https=)
EP (2) EP2836221B1 (https=)
JP (4) JP6491089B2 (https=)
CN (2) CN104244956B (https=)
CA (1) CA2870316C (https=)
ES (1) ES2959119T3 (https=)
MX (2) MX392972B (https=)
WO (1) WO2013155485A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104244956B (zh) * 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法
CA2905788C (en) 2013-03-12 2022-08-16 Emily A. Stein Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
EP4058570A4 (en) * 2019-11-11 2023-12-27 Atsuo Ochi METHOD AND KIT FOR REPROGRAMMING SOMATIC CELLS
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CA3189915A1 (en) * 2020-08-27 2022-03-03 Diana KERWIN Methods for the treatment of cardiovascular disease with cyclodextrins
IL300881A (en) * 2020-08-27 2023-04-01 Beren Therapeutics P B C Methods for preventing embolization of cholesterol crystals with cyclodextrins
KR20230096975A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
AU2022222756A1 (en) * 2021-02-18 2023-09-14 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
US20240238327A1 (en) * 2021-09-01 2024-07-18 Renatus Inc. Pharmaceutical composition comprising gamma-cyclodextrin polymer and uses thereof
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
ES2457017T3 (es) 2002-08-19 2014-04-24 Soho Flordis International Pty Ltd Composiciones que comprenden formadores de complejos con la grasa de la dieta y procedimientos para su uso
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) * 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
MY150649A (en) * 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
WO2010103823A1 (ja) 2009-03-12 2010-09-16 パナソニック株式会社 画像表示装置および画像表示方法
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
CN104244956B (zh) * 2012-04-13 2020-04-17 L&F研究有限公司 使用环糊精的方法

Similar Documents

Publication Publication Date Title
US20230338412A1 (en) Method of using cyclodextrin
JP2018203747A5 (https=)
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Liang et al. Andrographolide Ameliorates Diabetic Cardiomyopathy in Mice by Blockage of Oxidative Damage and NF‐κB‐Mediated Inflammation
Pisciotta et al. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
CN107613986A (zh) 用于组合疗法的药物组合物
US20100227841A1 (en) Patient populations and treatment methods
US20050032761A1 (en) Lipid profile modulation
CN105008394A (zh) 治疗结肠直肠癌的方法
US20250262190A1 (en) Use of lat1 inhibitors to treat obesity
KR102218498B1 (ko) Fxr 작용제들의 조합물
KR20190044667A (ko) Fxr 작용제의 신규 요법
US10758551B2 (en) Methods and compositions for treating pancreatitis
Zhou et al. Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells
HK40032085A (en) Method of using cyclodextrin
WO2011153209A2 (en) Cd36 inhibition to control obesity and insulin sensitivity
US20080020982A1 (en) Methods and compositions for treatment of atherosclerosis
WO2018027149A1 (en) Methods of treating alport syndrome
WO2025096597A1 (en) Compositions including inhibitors of pten expression or activity to prevent or treat type 2 diabetes